HER2 mutations, particularly exon 20 insertions, occur in approximately 2%–3% of NSCLC cases and are generally associated with poor prognosis and limited response to standard chemotherapy or immunotherapy (10). Here, ERBB2 is linked to non-small cell lung carcinoma.